Canadian medical technology company Kent Imaging has partnered with US-based wound healing research firm SerenaGroup to enhance wound tissue analysis by using near infrared imaging technology on its non-invasive KD203 device.
Kent’s hand-held, portable device is a tissue oxygenation measurement system designed to assess oxygen saturation (StO2), relative oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) levels in superficial tissue.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The imaging technology delivers 2D colour-coded images that offer the information necessary for clinicians to identify at-risk tissue.
These insights can also help in treatment decisions and optimise patient outcomes in wound care, plastic surgery and other reconstructive applications.
As part of the collaboration, SerenaGroup will use Kent’s technology as the standard of care for the assessment of wound oxygenation.
The technology will be integrated into the SerenaGroup facilities and used in future clinical and preclinical research.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSerenaGroup founder and medical director Dr Serena said: “One of the most troublesome and elusive criteria in treating wounds is the timely and accurate assessment of viable tissue.
“Kent’s device will propel us a long way down the healing path with a technology that has been lacking across the board in the Wound Care space.”
To date, SerenaGroup is said to have conducted more than 100 wound healing clinic trials.
Kent Imaging CEO Pierre Lemire said: “Our joint belief is that we can improve patient care and outcomes by significantly improving clinically relevant data that is required to assess and manage wounds.”
